{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:11:09Z","timestamp":1780643469654,"version":"3.54.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Sapropterin dihydrochloride is the first drug for the therapy of phenylketonuria, which is a rare disease that occurs one of 10,000\u201315,000 newborns. As a result, detailed and comprehensive reports on the safety of sapropterin in large, real-world populations are required. The purpose of this study is to undertake a complete analysis of sapropterin\u2019s adverse events (AEs) using the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrieved reports of adverse events with sapropterin as the principal suspect from FAERS between the first quarter of 2008 and the first quarter of 2024. The Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN) were utilized to detect AE signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study collected 4,953 suspected AE cases from the FAERS database, with sapropterin as the major suspect. A total of 130 positive signals were obtained utilizing the ROR, PRP, and BCPNN. The FAERS database revealed that common clinical AEs of sapropterin included vomiting, upper respiratory infection, rhinorrhea, and a reduction in amino acid concentrations. Furthermore, we detected probable unexpected adverse events (AEs) using disproportionality analysis, including gastroesophageal reflux disease, flatulence, influenza, ear infection, viral infection, pharyngitis streptococcal, spontaneous abortion, and nephrolithiasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>By analyzing huge amounts of real-world data from the FAERS database, we found potential novel AEs of sapropterin using disproportionate analysis. It is advantageous for healthcare professionals and pharmacists to focus on efficiently managing sapropterin\u2019s high-risk adverse events, improving drug levels in clinical settings, and ensuring patient medication safety.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1486597","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T04:38:22Z","timestamp":1729831102000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiahong","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuomiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/bcp.13159","article-title":"Factors affecting patient reporting of adverse drug reactions: a systematic review","volume":"83","author":"Al Dweik","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fpsyt.2019.00561","article-title":"Psychiatric and cognitive aspects of phenylketonuria: the limitations of diet and promise of new treatments","volume":"10","author":"Ashe","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00787-009-0738-8","article-title":"Executive dysfunction in treated phenylketonuric patients","volume":"18","author":"Azadi","year":"2009","journal-title":"Eur. Child. Adolesc. Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1517\/17425255.2013.804064","article-title":"Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias","volume":"9","author":"Blau","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/s0140-6736(10)60961-0","article-title":"Phenylketonuria","volume":"376","author":"Blau","year":"2010","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"155116","DOI":"10.1016\/j.metabol.2021.155116","article-title":"PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study","volume":"128","author":"Bratkovic","year":"2022","journal-title":"Metabolism"},{"key":"B7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ymgme.2018.09.006","article-title":"Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria","volume":"125","author":"Burton","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1037\/0894-4105.18.4.613","article-title":"Executive functioning, memory, and learning in phenylketonuria","volume":"18","author":"Channon","year":"2004","journal-title":"Neuropsychology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.ymgme.2009.10.007","article-title":"Executive function in early-treated phenylketonuria: profile and underlying mechanisms","volume":"99","author":"Christ","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1207\/s15326942dn3003_5","article-title":"Inhibitory control in children with phenylketonuria","volume":"30","author":"Christ","year":"2006","journal-title":"Dev. Neuropsychol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/jimd.12724","article-title":"Efficacy and safety of sapropterin before and during pregnancy: final analysis of the Kuvan\u00ae adult maternal paediatric European registry (KAMPER) maternal and phenylketonuria developmental outcomes and safety (PKUDOS) PKU-MOMs sub-registries","volume":"47","author":"Feillet","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"102626","DOI":"10.1016\/j.conb.2022.102626","article-title":"Dopamine and norepinephrine are embracing their immune side and so should we","volume":"77","author":"Gaskill","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ymgme.2014.02.016","article-title":"Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry","volume":"112","author":"Grange","year":"2014","journal-title":"Mol. Genet. Metabolism"},{"key":"B14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/B978-0-323-85492-4.00045-4","article-title":"Chapter 87 - deficiencies of tetrahydrobiopterin, tyrosine hydroxylase, and aromatic L-amino acid decarboxylase","volume-title":"Primer on the autonomic nervous system","author":"Hyland","year":"2023"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e5768","DOI":"10.1002\/pds.5768","article-title":"Adverse drug reaction signal detection methods in spontaneous reporting system: a systematic review","volume":"33","author":"Jiao","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s10038-018-0529-5","article-title":"Tetrahydrobipterin-responsive phenylalanine hydroxylase deficiency","volume":"64","author":"Kure","year":"2019","journal-title":"J. Hum. Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1002\/ajmg.a.32562","article-title":"Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria","author":"Lee","year":"2008","journal-title":"Am. J. Med. Genet. A"},{"key":"B18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/s0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-019-01079-z","article-title":"Phenylketonuria: current treatments and future developments","volume":"79","author":"Lichter-Konecki","year":"2019","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.ymgme.2015.02.003","article-title":"Long-term safety and efficacy of sapropterin: the PKUDOS registry experience","volume":"114","author":"Longo","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrgastro.2013.105","article-title":"Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets","volume":"10","author":"Mawe","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/jnc.15600","article-title":"Perturbation of monoamine metabolism and enhanced fear responses in mice defective in the regeneration of tetrahydrobiopterin","volume":"161","author":"Miyajima","year":"2022","journal-title":"J. Neurochem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-017-0600-x","article-title":"Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial","volume":"12","author":"Muntau","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s13023-021-01968-1","article-title":"Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial","volume":"16","author":"Muntau","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13023-020-01379-8","article-title":"Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH(4)) deficiencies","volume":"15","author":"Opladen","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.fertnstert.2013.06.008","article-title":"Unexplained pregnancy loss: a marker of basal endothelial dysfunction?","volume":"100","author":"Pasquier","year":"2013","journal-title":"Fertil. Steril."},{"key":"B27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/bcp.13886","article-title":"Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: a meta-analysis of randomized controlled trials","volume":"85","author":"Qu","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"107583","DOI":"10.1016\/j.ymgme.2023.107583","article-title":"Phenylketonuria and the brain","volume":"139","author":"Rovelli","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2165\/00003495-200969040-00006","article-title":"Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia","volume":"69","author":"Sanford","year":"2009","journal-title":"Drugs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jpeds.2014.08.003","article-title":"Sapropterin is safe and effective in patients less than 4-years-old with BH4-responsive phenylalanine hydrolase deficiency","volume":"165","author":"Shintaku","year":"2014","journal-title":"J. Pediatr."},{"key":"B31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/ped.14399","article-title":"Guide for diagnosis and treatment of hyperphenylalaninemia","volume":"63","author":"Shintaku","year":"2021","journal-title":"Pediatr. Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e14939","DOI":"10.1111\/ped.14939","article-title":"Sapropterin for phenylketonuria: a Japanese post-marketing surveillance study","volume":"64","author":"Tamura","year":"2022","journal-title":"Pediatr. Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study","volume":"154","author":"Trefz","year":"2009","journal-title":"J. Pediatr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1037\/\/0894-4105.15.2.221","article-title":"Deficits in memory strategy use related to prefrontal dysfunction during early development: evidence from children with phenylketonuria","volume":"15","author":"White","year":"2001","journal-title":"Neuropsychology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1515\/jpem-2021-0077","article-title":"Birth prevalence of tetrahydrobiopterin deficiency in China: data from the national newborn screening program, 2013-2019","volume":"34","author":"Yuan","year":"2021","journal-title":"J. Pediatr. Endocrinol. Metab."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1486597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T04:38:24Z","timestamp":1729831104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1486597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":36,"alternative-id":["10.3389\/fphar.2024.1486597"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1486597","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"article-number":"1486597"}}